Compare Incyte Corporation (INCY) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Roundhill Magnificent Seven ETF — how do they compare? Incyte Corporation trades at $120.77 (market cap $24.54B), while Roundhill Magnificent Seven ETF trades at $67.71. Which is the better fit depends on your goals.
| INCY | MAGS | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $70.94 |
52-Week Low | $81.66 | $55.39 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
MAGS (Roundhill Magnificent Seven ETF) trades at $67.71, down 1.93% amid broader rotation away from concentrated tech exposure. Technical indicators show bullish moving averages but overbought RSI levels, with key support at $67. Recent news highlights the ETF's 181% gain since launch but notes underperformance versus the S&P 500 this year as AI spending pressures tech balance sheets.
The ETF faces headwinds from compressed hyperscaler valuations and declining payout ratios, though AI revenue growth potential remains. Risks include concentration in seven mega-caps and market broadening away from tech leadership. Analyst sentiment is mixed, balancing long-term AI themes against near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
